Publications by authors named "Blanca Navarro-Llinas"
Cancer cachexia manifests as whole body wasting, however, the precise mechanisms governing the alterations in skeletal muscle and cardiac anabolism have yet to be fully elucidated. In this study, we explored changes in anabolic processes in both skeletal and cardiac muscles in the Yoshida AH-130 ascites hepatoma model of cancer cachexia. AH-130 tumor-bearing rats experienced significant losses in body weight, skeletal muscle, and heart mass.
View Article and Find Full Text PDFArticle Synopsis
- Anti-EGFR antibodies have limited effectiveness in breast cancer due to compensatory pathways and resistance in triple-negative breast cancer (TNBC) from CDK2/cyclin E expression; however, a cetuximab-based antibody drug conjugate (ADC) incorporating a CDK inhibitor may improve targeted treatment.
- In experimental designs, researchers evaluated the expressions of cell cycle regulators alongside EGFR and developed an ADC, combining cetuximab with CDK inhibitor SNS-032, to specifically deliver treatment to EGFR-expressing cancer cells.
- Results showed that the ADC effectively inhibited tumor growth, induced cytotoxic effects on high EGFR-expressing cells, and demonstrated potential for improved targeting in aggressive breast cancer types, highlighting the importance